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Open access under CC BY license.Methylationofhistone tails isbelieved tobe important for
the establishment and inheritance of gene expression
programs during development. Jarid2/Jumonji is the
foundingmember of a family of chromatinmodifierswith
histone demethylase activity. Although Jarid2 contains
amino acid substitutions that are thought to abolish its
catalytic activity, it is essential for the development of
multiple organs in mice. Recent studies have shown that
Jarid2 is a component of the polycomb repressive com-
plex 2 and is required for embryonic stem (ES) cell differ-
entiation. Here, we discuss current literature on the
function of Jarid2 and hypothesize that defects resulting
from Jarid2 deficiency arise from a failure to correctly
primegenes in ES cells that are required for later stages in
development.
Introduction
In eukaryotic cells, DNA is wrapped around nucleosomes
composed of an octamer of the core histonesH2A, H2B, H3
and H4. Linker histone H1 can facilitate further packag-
ing of nucleosomes into a higher-order chromatin struc-
ture. Histone tails that extrude from the core octamer can
be post-translationally modified by a number of different
processes, including methylation, acetylation, phosphor-
ylation, ubiquitylation and SUMOylation. Methylation
targets lysine and arginine residues and these modifica-
tions can have a profound impact on the regulation and
inheritance of transcriptional programs. Histone methyl-
ation is thought to be important for activating gene ex-
pression (e.g., trimethylation of lysine 4 on histone H3
[H3K4me3]) and for silencing gene activity (e.g., trimethy-
lation of lysine 27 on histone H3 [H3K27me3]). Historical-
ly, methylation of histones was considered to be a
relatively stable modification, in contrast to histone acet-
ylation. However, in the last few years many enzymes
capable of antagonizing the addition ofmethyl groups or of
directly removing methyl groups from histones have been
identified [1]. The largest family of histone demethylases
identified so far is the Jumonji family, of which the found-
ing member is Jarid2/Jumonji [2]. These proteins contain
a Jumonji C (JmjC) domain that is believed to catalyze
histone demethylation. In the case of Jarid2, alterations in
the proposed catalytic site at the core of the JmjC domain
are predicted to impair its catalytic activity [2], and
yet Jarid2 is apparently indispensable for normal
development.Corresponding author: Fisher, A.G. (amanda.fisher@csc.mrc.ac.uk).
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development [3,4]. The molecular mechanism by which
this inactive histone demethylase modulates mammalian
development is not well understood, but recent studies
have shown that Jarid2 associates with polycomb group
(PcG) proteins in several cell types, including embryonic
stem (ES) cells, thymocytes, HeLa and HEK 293T fibro-
blasts, and is critical for ES cell differentiation [5–9]. PcG
proteins were identified more than 30 years ago as reg-
ulators of Hox genes and development in Drosophila mel-
anogaster [10,11] and are currently thought to regulate
gene expression during development and patterning in
many organisms [12,13]. PcG proteins also have a critical
role in adult tissue homeostasis because abnormal expres-
sion can promote tumor formation and cancer in various
tissues [13,14]. Here, we examine current knowledge about
the role of Jarid2 inmammals and discuss how the recently
reported interaction of Jarid2 with PcG proteins is critical
for preparing ES cells for differentiation by facilitating the
transcriptional priming of developmental regulator genes.
This proposed role for Jarid2might provide an explanation
of the reported pleiotropic effects of Jarid2 removal during
embryogenesis.
The Jumonji family of histone demethylases
Jarid2 contains a JmjC domain and has extensive homolo-
gy to a large group of evolutionarily conserved proteins
known as the Jumonji family [2]. Proteins in this family
each contain a JmjC domain that is important for catalyz-
ing the removal of methyl groups from specific lysine
residues on histones through an oxidative reaction that
requires iron and a-ketoglutarate as cofactors. Jumonji
proteins demethylate lysines in histone H3 at positions
4, 9, 27 and 36 (Figure 1a) [15–33]. Jarid2 shares the
highest degree of homology with Jarid1 proteins, which
are capable of recognizing and removing methyl groups
from di- (me2) and trimethylated (me3) histone H3K4
(Figure 1a) [20–22]. Jarid1 contains at least six functional
domains (Figure 1b), including two plant homeodomain
(PHD) zinc-finger domains that are not present in Jarid2
[2]. Both proteins contain Jumonji N (JmjN), AT-rich
interaction domain (ARID), and a zinc finger (ZF), in
addition to JmjC. In the case of Jarid2, however, altera-
tions in the underlying amino acid sequence within the
predicted cofactor binding site at the core of the JmjC
domain are predicted to abolish or severely impair the
histone demethylase activity of the resulting protein
(Figure 1c, asterisks) [2] and no demethylating activitycb.2010.10.004 Trends in Cell Biology, February 2011, Vol. 21, No. 2
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Figure 1. Jarid2 belongs to the JmjC-domain-containing family of proteins. (a) Several proteins that contain a JmjC domain catalyze the removal of methyl groups from
lysine residues at specific positions on histone H3, as indicated. n.d., not determined. (b) Comparison of functional domains within the Jarid2 and Jarid1 proteins: Jumonji
N (JmjN), AT-rich interaction domain (ARID), plant homeodomain zinc finger domain (PHD), Jumonji C (JmjC) and C5HC2 zinc finger (ZF). In addition, the N terminus of
Jarid2 contains a nuclear localization sequence (aa 1–131) and a trans-repression domain (aa 132–222). (c) Amino acid sequence alignment of the JmjC domain of mouse
Jarid1 and Jarid2 proteins. Asterisks indicate the amino acids that are critical for cofactor (iron and a-ketoglutarate) binding. Conserved amino acids are highlighted in grey.
(d) Alignment of the amino acid sequence of the JmjC domains of Jarid2 proteins in different organisms; conserved residues are highlighted in grey.
Opinion Trends in Cell Biology February 2011, Vol. 21, No. 2for this protein has been demonstrated to date. In view of
this, it is perhaps surprising that the altered JmjC domain
contained within Jarid2 is highly conserved (Figure 1d), a
result that suggests that Jarid2 has a function that might
be independent of histone demethylation. Although there
are currently no biochemical data to support an alternative
role for Jarid2, it has been claimed that its ARID and ZF
domains directly bind DNA [8,34,35], albeit with low affin-
ity [36]. In addition to these conserved domains, the N
terminus of Jarid2 contains a nuclear localization se-
quence (Figure 1b) and a trans-repression domain that
is required for repressor activity in Gal4 reporter systems
[7,34].
Jarid2 in the developing embryo
Jarid2/Jumonji was identified in 1995 as a regulator of
neural development, in a gene trap mutagenesis screen in
mice [37]. It was named Jumonji because of the cruciform
shape of neural grooves (Jumonji means cruciform in
Japanese) observed in Jarid2-targeted embryos. Subse-
quent studies showed that Jarid2 is expressed by a re-stricted population of cells within the developing mouse
brain, heart, spinal cord, liver and thymus [3,4]. Jarid2-
deficiency resulted in a range of phenotypes, the severity
and developmental onset of which were dependent on the
genetic background against which chimeras were made
and backcrossed (Table 1). For example, embryos generat-
ed from targeted ES cells [37] showed defects in neural
tube formation [37], neural and heart development [38–42]
or hypoplasia of liver, thymus and spleen, together with
impaired definitive hematopoiesis [38,43,44]. Embryo le-
thality ensues between 10.5 and 15.5 days of gestation,
according to strain, and is multi-factorial. The availability
of new, independently derived gene-trap lines [45,46] and
ES cells containing Jarid2 floxed alleles [6,9,47] will facili-
tate verification and systematic examination of these com-
plex phenotypes and investigation of the mechanisms that
partially compensate for Jarid2 loss in vivo. Genetic anal-
yses have also shown that mutations in the JARID2 gene
are associated with several congenital defects in humans,
including nonsyndromic cleft lip [48], spina bifida and
congenital heart defects [49], as well as with schizophrenia75
Table 1. Morphological abnormalities in Jarid2-deficient mice
Mutagenesis strategy Mouse strain Lethality Developmental abnormality Refs
Gene trap (intron 2) in
E14 ES cells (transfection)
Mixed Balb/cA
and 129/Ola
E10.5–E15.5 Defects in neural tube formation [37]
Same as above Balb/cA E15.5 Hypoplasia of liver, thymus and spleen;
impaired definitive hematopoiesis
[38,43,44]
Same as above C3H/HeJ E11.5 Defects in neural tube and heart formation [38–42]
Gene trap (intron 2) in R1
ES cells (retrovirus)
C57BL/C6 At birth Heart formation defects; leaky expression
of Jarid2 in nervous system
[45,46]
Floxed (exon 3) by targeting
in 129/Sv ES cells
C57BL/C6 Not applicable Mutation of Jarid2 alleles specifically in
cardiomyocytes on day E7.5 (aMHC-Cre)
does not result in embryonic lethality
[47]
Opinion Trends in Cell Biology February 2011, Vol. 21, No. 2[50,51]. JARID2 is expressed by cells in the adult brain and
heart in humans [52,53], mimicking previous observations
in mouse adult heart, skeletal muscle, kidney, brain, and
thymus [3,4]. Although we do not currently understand the
basis of the association of JARID2 mutation with these
human diseases, collectively these data underscore the
pleiotropic role of JARID2 in the development and homeo-
stasis of many tissues.
Jarid2 in the developing heart: a critical regulator of cell
proliferation?
The role of Jarid2 in the developing embryo is not well
understood. Most studies to date have examined abnor-
malities arising in the developing heart and nervous sys-
tem in Jarid2-targeted embryos. It has been suggested
that Jarid2 modulates cardiomyocyte proliferation and
coordinates cell cycle exit during neurogenesis by directly
repressing transcription of cyclin D1 [3,40,42]. Experi-
ments in which Flag-tagged Jarid2 was over-expressed
in fibroblasts have suggested that Jarid2 promotes the
recruitment of histone methyltransferases (G9a and
GLP) to, and subsequent H3K9 methylation of, the cyclin
D1 promoter in vitro [54] (Table 2). Although this provides
a plausible model of the action of Jarid2 in regulating
proliferation in the heart, it is not yet known whether
endogenous Jarid2, G9a and GLP interact directly in
primary cardiomyocytes, and double-mutant embryos
lacking both Jarid2 and cyclin D1 do not show complete
reversion to a wild-type phenotype [40]. It has also been
proposed that Jarid2 modulates the activity of other tran-
scription factors and cell-cycle regulators (Table 2), includ-
ing Gata4 [55], Rb protein [56], MEF2A [57], Zfp496 [58]
and Nkx2.5 [55], a cardiac-associated regulator that
represses Jarid2 expression in the heart [59].
In mice, the absence of Jarid2 increases proliferation of
cardiomyocytes [40], megakaryocytes [60], fibroblasts
[61,62] and cells within the developing brain [42]. At theTable 2. Reported Jarid2-interacting proteins and candidate targe
Interacting protein Method
Nkx2.5 and Gata4 Overexpression followed by in vivo protein
IP in fibroblasts
Rb protein In vitro GST pull down using cardiomyocytes ly
Mef2a In vitro GST pull down using cardiomyocytes ly
Zfp496 In vitro GST pull down using heart extracts
G9a and GLP Overexpression followed by in vivo protein
IP in fibroblast
Polycomb repressive
complex 2
Mass spectrometry, gel filtration and in vivo pr
IP in ES cells
76same time, differentiation of cardiomyocytes [39] and
hepatocytes [63] is partially impaired in Jarid2-targeted
embryos. This suggests that Jarid2 is important for main-
taining the correct balance between proliferation and dif-
ferentiation, and that in some circumstances Jarid2might
act as a tumor suppressor gene. This conjecture is sup-
ported by findings showing that Jarid2 expression is down-
regulated by the oncogenic microRNA miR-155 in B-cell
tumors [61] and that Jarid2 is a candidate in genetic
screens for factors that override senescence (J. Gil, person-
al communication).
Jarid2 is a PRC2 component in ES cells and is required
for gene priming
ES cells are derived from the inner cell mass of pre-im-
plantation blastocysts, from which all the cells of the adult
soma are derived. These cells retain a potential to self-
renew and to differentiate into the three germ layers under
appropriate conditions and therefore are classed as plurip-
otent. Although Jarid2 has been regularly listed as a key
component in transcriptional networks that underlie plur-
ipotency in both mouse and human ES cells [64–68], the
nature of the role of Jarid2 in pluripotency has, until
recently, been unclear. Recently, several groups reported
that Jarid2 associates with PcG proteins in ES cells and
that Jarid2 is important for successful ES cell differentia-
tion (K.P. Yan and R. Shiekhattar, personal communica-
tion) [5–9].
PcG proteins regulate gene expression during embryon-
ic development [12,13] and form multi-component com-
plexes that are capable of modifying histone tails within
chromatin. Polycomb repressor complexes (PRCs) act se-
quentially, and a widely accepted model suggests that
PRC2 (which contains the core subunits Eed, Suz12 and
Ezh2) methylates H3K27 (H3K27me3) through its catalyt-
ic subunit Ezh2. PRC1 (which contains the subunits
Ring1A and/or Ring1B, Bmi1 and/or Mel18, Cbx subunitst genes
Target gene(s) Cell type Refs
Anf Primary cardiomyocytes [55]
sates Cyclin D1 Primary cardiomyocytes [56]
sates aMHC/Myh6 Primary cardiomyocytes [57]
Unknown [58]
Cyclin D1 Fibroblast [54]
otein High number
of developmental
regulators
Embryonic stem cells [5–9]
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Figure 2. Jarid2 is required for Ser5-phosphorylated RNAPII recruitment to bivalent domains in undifferentiated mouse ES cells. In pluripotent ES cells, establishment of
primed chromatin involves the recruitment of Ser5-phosphorylated RNAPII (green) to the promoter regions (flag) of PRC-repressed target genes. PRC2 subunits (red)
methylate H3K27, providing a docking site for PRC1 and Ring1A/B-mediated mono-ubiquitination of H2A (blue). Loss of PRC-mediated repression on ES cell differentiation
results in productive gene expression. In Jarid2 null ES cells, Ser5-phosphorylated RNAPII is not efficiently recruited to PRC-repressed genes. This lack of priming results in
the failure of mutant cells to efficiently express target genes when induced to differentiate.
Opinion Trends in Cell Biology February 2011, Vol. 21, No. 2and Phc subunits) binds H3K27me3 and catalyzes the
mono-ubiquitination of lysine 119 on H2A (H2AK119ub1)
through the E3 protein ligase subunits Ring1A andRing1B
(Figure 2) [12,69]. It has been shown that PRC1 recruit-
ment at certain loci occurs independently of H3K27me3
[12,70], which suggests that these recruitment events can
be uncoupled. Recruitment of PRC can in turn lead to
transcriptional repression of selected target genes by
mechanisms that are not fully understood, but are likely
to involve both physical compaction and the inhibition of
efficient transcriptional elongation by locally bound RNA
polymerase II (RNAPII). In ES cells, PRC1 and PRC2
binding is enriched at the promoters of hundreds of genes,
many of which encode transcription factors that are acti-
vated as ES cells differentiate and have important roles in
development [71–76]. The promoters of these genes have
not only H3K27me3 in ES cells, but also histone marks
that are associated with transcriptionally active domains,
including H3K4me3 [73,77]. This opposing configuration,
often referred to as bivalent chromatin, has been detected
in ES and other cell types [78] and is characterized by the
presence of bound RNAPII in which Ser5-phosphorylated
(the initiating form of RNAPII), rather than Ser2-phos-
phorylated forms (characteristic of elongating RNAPII)
predominate (Figure 2) [74,79]. On the basis of these
observations, we and others have proposed that the selec-
tive priming of developmental regulator genes in ES cells
(co-enriched for RNAPII and PRCs) might be functionally
relevant in enabling these cells to execute different lineage
programs in response to specific cues [80–82]. In other
words, genes for which RNAPII is already loaded (but
restrained from generating mature full-length transcripts
because of bound PRC) might be primed for fast and
efficient activation in response to differentiation-mediated
PRC withdrawal.
In the last year, several studies have provided compel-
ling evidence that Jarid2 is a component of PRC2 in ES
cells and that Jarid2 and PRC2 bind to a largely over-
lapping set of target genes (>90% in common genome-
wide). Jarid2 seems to be required for efficient binding
of PRC2 and PRC1 to target genes [5–9], although ChIP
analysis in Jarid2 knockdown [5,7,8] or knockout ES cells
[6,9] did not show a consistent change in H3K27 methyla-tion levels; in three studies, H3K27me3 decreased follow-
ing Jarid2 depletion [7–9], whereas loss of Jarid2 resulted
in either no change [5] or enhanced H3K27me3 at similar
target genes [6] in other studies. This apparent lack of
consensus suggests that although reduced binding of PRC2
to target genes is a feature of Jarid2 depletion, this might
have variable consequences for H3K27me3 levels. The
interpretation by Orkin and Wysocka is that Jarid2 acts
as a molecular rheostat and fine-tunes PRC2 functions
by interfering with H3K27 methyltransferase activity
[5,6,83]. Conversely, Reinberg and Helin claim that Jarid2
is important primarily for targeting PRC2 to target genes,
but can also stimulate H3K27 methyltransferase activity
[7,8]. In vitro experiments using nucleosomes and recom-
binant PRC2 and Jarid2 proteins have failed to show any
consistency; Jarid2 can stimulate [8] or inhibit [5,6] the
methyltransferase activity of PRC2 towards H3K27. One
explanation that might reconcile these opposing views is
that binding of Ezh2 to PRC2 target genes is diminished
but not abolished in Jarid2/ cells, such that the activity
of remaining Ezh2 is sufficient to maintain H3K27me3
levels, at least at certain genes. Moreover, compensatory
mechanisms, perhaps involving the redundant H3K27
methyltransferase Ezh1 [76], could also be operating in
Jarid2-depleted cells. The fact that some Ezh2, Suz12 and
Eed is still selectively recruited to PRC2 targets in
Jarid2/ ES cells [6,9] confirms that PRC2 can be
recruited in a Jarid2-independent manner.
Although discrepancies in H3K27me3 levels in the var-
ious Jarid2-deficient cell lines analyzed remain unre-
solved, the fact that the effects of Jarid2 removal on
H3K27me3 levels are modest makes it unlikely that they
could fully account for the phenotypic abnormalities of
Jarid2/ ES cells – namely, grossly impaired ability to
differentiate and increased proliferation. In addition,
Jarid2/ ES cells do not display the genome-wide dere-
pression of PRC2 target genes that is characteristic of the
withdrawal of other PRC2 components, including Eed,
Ezh2 and Suz12 [71,73,75,76]. If anything, PRC2 target
gene expression was lower in Jarid2/ ES cells than in
controls [6,9]. This suggests that Jarid2 does not function
as a conventional core repressive component in PRC2,
unlike Eed, Suz12 and Ezh2. In agreement with this,77
Opinion Trends in Cell Biology February 2011, Vol. 21, No. 2Jarid2/ ES cells reprogrammed somatic cells efficiently
in heterokaryon reprogramming assays, whereas ES cells
lacking Eed, Suz12 or Ezh2 fail to reprogram somatic cells
because they inappropriately express PRC2-regulated fac-
tors that interfere with conversion to pluripotency [84].
A clue to the role of Jarid2 came with the discovery that
bivalent domains in Jarid2/ ES cells lacked Ser5-phos-
phorylated RNAPII enrichment [9]. It has been proposed
that this form of RNAPII characterizes primed genes
before productive transcription. When induced to differen-
tiate to mesoderm, endoderm or neural ectoderm, Jarid2/
 ES cells were unable to initiate gene expression pro-
grams associated with each differentiation pathway and
did not elicit the productive transcription of PRC2 target
genes [6–9]. Collectively, these results suggest that Jarid2
is required to establish or maintain Ser5-phosphorylated
RNAPII at bivalent/PRC2-repressed domains in ES cells
and, more importantly, that priming of this subset of genes
is important for ES cell function (Figure 2).
Conclusions and future perspectives
Jarid2 has previously been implicated as a regulator of
embryonic development through a mechanism thought to
involve Jarid2-mediated recruitment ofH3K9methyltrans-
ferase complexes (G9a and GLP) to the cyclin D1 promoter
[54].Recent studiesnow indicate thatJarid2associateswith
the H3K27 histone methyltransferase complex PRC2 in
undifferentiated ES cells, which regulates myriad develop-
mental regulator genes required for subsequent ES cell
differentiation. Jarid2-deficient ES cells differentiate inef-
ficiently in vitro, which suggests that Jarid2 is required for
execution of the very early stages of development in vivo.
However, Jarid2-targeted embryos develop through gastru-
lation and show pleiotropic defects only later during organ-
ogenesis. This apparent contradiction of when and where
Jarid2 acts in vitro versus in vivo might have a number of
different explanations. First, it is possible that leaky expres-
sion from gene-trapped Jarid2 alleles might occur in tar-
geted embryos, or that maternally derived Jarid2
transcripts provide a significant contribution to the devel-
oping embryo. Second, any requirement for Jarid2might be
selectively compensated by other factors or signaling path-
ways in vivo, at least up to late gastrulation stages. Alter-
natively, it is possible that Jarid2 is only required to enable
in vitro cultured ES cells to successfully escape their prolif-
erative cycle and exit fromself-renewal.Althoughwe cannot
rule out these possibilities at present, it seems unlikely that
the role of Jarid2 in early development is limited to ES cells,
because it is also required for successful gastrulation in
Xenopus laevis [5]. Maternal contribution of Jarid2 tran-
scripts isworth considering because JARID2 is expressed in
human mature oocytes [85] and its role in Xenopus gastru-
lation has been assayed using Jarid2 morpholinos that
would blockmaternal transcripts [5]. In addition, the varia-
tion in phenotypes observed when Jarid2-targetedmice are
bred onto different genetic backgrounds supports the idea
that compensatory mechanisms in vivo could effectively
mask a role for Jarid2 in early development. Finally, it is
perhaps worth pointing out that self-renewing pluripotent
cells in vivo are transient and limited to a very tightwindow
indevelopment (blastocyst stage) [86]. In the caseofEScells,78for which pluripotent self-renewal has been artificially pro-
longed, it might be far harder for compensatory mechan-
isms, such as Ezh1, to operate successfully. This might
explain why embryos lacking Jarid2 successfully develop
right up to gastrulation whereas Jarid2/ ES cells show
more pronounced differentiation defects.
The capacity of ES cells to self-renew and give rise to
progeny for many different cell types is not yet understood
at the molecular level. The discovery of so-called bivalent
chromatin domains, for which the transcriptional machin-
ery and PRC1 and PRC2 complexes are co-recruited to a
cohort of non-expressed but primed genes, might provide
some important insights into how genomic flexibility is
underwritten. This process seems to require Jarid2 and
enables cells to efficiently transit from pluripotent to dif-
ferentiated states. Although there is still much to do,
particularly in understanding the molecular relationship
between Jarid2, PRC and Ser5-phosphorylated RNAPII, it
is likely that this work will further our understanding of
how ES cells retain their capacity to self-renew and differ-
entiate into multiple lineages.
Acknowledgements
We thank Cynthia Fisher for critical reading of the manuscript and the
Medical Research Council UK for continued support of D.L. and A.G.F.
References
1 Pedersen, M.T. and Helin, K. (2010) Histone demethylases in
development and disease. Trends Cell Biol. 20, 662–671
2 Klose, R.J. et al. (2006) JmjC-domain-containing proteins and histone
demethylation. Nat. Rev. Genet. 7, 715–727
3 Takeuchi, T. et al. (2006) Roles of jumonji and jumonji family genes in
chromatin regulation and development. Dev. Dyn. 235, 2449–2459
4 Jung, J. et al. (2005) Roles of JUMONJI in mouse embryonic
development. Dev. Dyn. 232, 21–32
5 Peng, J.C. et al. (2009) Jarid2/Jumonji coordinates control of PRC2
enzymatic activity and target gene occupancy in pluripotent cells. Cell
139, 1290–1302
6 Shen, X. et al. (2009) Jumonji modulates polycomb activity and self-
renewal versus differentiation of stem cells. Cell 139, 1303–1314
7 Pasini, D. et al. (2010) JARID2 regulates binding of the Polycomb
repressive complex 2 to target genes in ES cells. Nature 464, 306–
310
8 Li, G. et al. (2010) Jarid2 and PRC2, partners in regulating gene
expression. Genes Dev. 24, 368–380
9 Landeira, D. et al. (2010) Jarid2 is a PRC2 component in embryonic
stem cells required for multi-lineage differentiation and recruitment of
PRC1 and RNA polymerase II to developmental regulators. Nat. Cell
Biol. 12, 618–624
10 Struhl, G. (1981) A gene product required for correct initiation of
segmental determination in Drosophila. Nature 293, 36–41
11 Lewis, E.B. (1978) A gene complex controlling segmentation in
Drosophila. Nature 276, 565–570
12 Simon, J.A. and Kingston, R.E. (2009) Mechanisms of polycomb gene
silencing: knowns and unknowns.Nat. Rev. Mol. Cell Biol. 10, 697–708
13 Sparmann, A. and van Lohuizen, M. (2006) Polycomb silencers control
cell fate, development and cancer. Nat. Rev. Cancer 6, 846–856
14 Bracken, A.P. and Helin, K. (2009) Polycomb group proteins: navigators
of lineage pathways led astray in cancer. Nat. Rev. Cancer 9, 773–784
15 Tsukada, Y. et al. (2006) Histone demethylation by a family of JmjC
domain-containing proteins. Nature 439, 811–816
16 Frescas, D. et al. (2007) JHDM1B/FBXL10 is a nucleolar protein that
represses transcription of ribosomal RNA genes. Nature 450, 309–313
17 Feng, W. et al. (2010) PHF8 activates transcription of rRNA genes
through H3K4me3 binding and H3K9me1/2 demethylation. Nat.
Struct. Mol. Biol. 17, 445–450
18 Horton, J.R. et al. (2010)Enzymatic and structural insights for substrate
specificity ofa familyof jumonji histone lysinedemethylases.Nat.Struct.
Mol. Biol. 17, 38–43
Opinion Trends in Cell Biology February 2011, Vol. 21, No. 219 Fortschegger, K. et al. (2010) PHF8 targets histone methylation and
RNA polymerase II to activate transcription.Mol. Cell Biol. 30, 3286–
3298
20 Christensen, J. et al. (2007) RBP2 belongs to a family of demethylases,
specific for tri-and dimethylated lysine 4 on histone 3. Cell 128, 1063–
1076
21 Lee, M.G. et al. (2007) Physical and functional association of a
trimethyl H3K4 demethylase and Ring6a/MBLR, a polycomb-like
protein. Cell 128, 877–887
22 Iwase, S. et al. (2007) The X-linked mental retardation gene SMCX/
JARID1C defines a family of histone H3 lysine 4 demethylases. Cell
128, 1077–1088
23 Cloos, P.A. et al. (2006) The putative oncogene GASC1 demethylates
tri- and dimethylated lysine 9 on histone H3. Nature 442, 307–311
24 Fodor, B.D. et al. (2006) Jmjd2b antagonizes H3K9 trimethylation at
pericentric heterochromatin in mammalian cells. Genes Dev. 20, 1557–
1562
25 Klose, R.J. et al. (2006) The transcriptional repressor JHDM3A
demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature
442, 312–316
26 Whetstine, J.R. et al. (2006) Reversal of histone lysine trimethylation
by the JMJD2 family of histone demethylases. Cell 125, 467–481
27 Agger, K. et al. (2007) UTX and JMJD3 are histone H3K27
demethylases involved in HOX gene regulation and development.
Nature 449, 731–734
28 Lan, F. et al. (2007) A histone H3 lysine 27 demethylase regulates
animal posterior development. Nature 449, 689–694
29 Lee, M.G. et al. (2007) Demethylation of H3K27 regulates polycomb
recruitment and H2A ubiquitination. Science 318, 447–450
30 De Santa, F. et al. (2007) The histone H3 lysine-27 demethylase Jmjd3
links inflammation to inhibition of polycomb-mediated gene silencing.
Cell 130, 1083–1094
31 Yamane, K. et al. (2006) JHDM2A, a JmjC-containing H3K9
demethylase, facilitates transcription activation by androgen
receptor. Cell 125, 483–495
32 Sinha, K.M. et al. (2010) Regulation of the osteoblast-specific
transcription factor Osterix by NO66, a Jumonji family histone
demethylase. EMBO J. 29, 68–79
33 Hsia, D.A. et al. (2010) KDM8, a H3K36me2 histone demethylase that
acts in the cyclin A1 coding region to regulate cancer cell proliferation.
Proc. Natl. Acad. Sci. U. S. A. 107, 9671–9676
34 Kim, T.G. et al. (2003) JUMONJI, a critical factor for cardiac
development, functions as a transcriptional repressor. J. Biol. Chem.
278, 42247–42255
35 Patsialou, A. et al. (2005) DNA-binding properties of ARID family
proteins. Nucleic Acids Res. 33, 66–80
36 Kusunoki, H. et al. (2009) Solution structure of the AT-rich interaction
domain of Jumonji/JARID2. Proteins 76, 1023–1028
37 Takeuchi, T. et al. (1995) Gene trap capture of a novel mouse gene,
jumonji, required for neural tube formation. Genes Dev. 9, 1211–1222
38 Ohno, T. et al. (2004) Modifiers of the jumonji mutation downregulate
cyclin D1 expression and cardiac cell proliferation. Biochem. Biophys.
Res. Commun. 317, 925–929
39 Takeuchi, T. et al. (1999) jumonji gene is essential for the neurulation
and cardiac development of mouse embryos with a C3H/He
background. Mech. Dev. 86, 29–38
40 Toyoda, M. et al. (2003) jumonji downregulates cardiac cell
proliferation by repressing cyclin D1 expression. Dev. Cell 5, 85–97
41 Takahashi, M. et al. (2004) Cardiac abnormalities cause early lethality
of jumonji mutant mice. Biochem. Biophys. Res. Commun. 324, 1319–
1323
42 Takahashi, M. et al. (2007) Functions of a jumonji-cyclin D1 pathway in
the coordination of cell cycle exit and migration during neurogenesis in
the mouse hindbrain. Dev. Biol. 303, 549–560
43 Motoyama, J. et al. (1997) Organogenesis of the liver, thymus and
spleen is affected in jumonji mutant mice. Mech. Dev. 66, 27–37
44 Kitajima, K. et al. (1999) Definitive but not primitive hematopoiesis is
impaired in jumonji mutant mice. Blood 93, 87–95
45 Baker, R.K. et al. (1997) In vitro preselection of gene-trapped
embryonic stem cell clones for characterizing novel developmentally
regulated genes in the mouse. Dev. Biol. 185, 201–214
46 Lee, Y. et al. (2000) Jumonji, a nuclear protein that is necessary for
normal heart development. Circ. Res. 86, 932–93847 Mysliwiec, M.R. et al. (2006) Generation of a conditional null allele of
jumonji. Genesis 44, 407–411
48 Scapoli, L. et al. (2010) Expression and association data strongly
support JARID2 involvement in nonsyndromic cleft lip with or
without cleft palate. Hum. Mutat. 31, 794–800
49 Volcik, K.A. et al. (2004) Evaluation of the jumonji gene and risk for
spina bifida and congenital heart defects. Am. J. Med. Genet. A 126A,
215–217
50 Liu, Y. et al. (2009) Whole genome association study in a homogenous
population in Shandong peninsula of China reveals JARID2 as a
susceptibility gene for schizophrenia. J. Biomed. Biotechnol. 2009,
536918
51 Pedrosa, E. et al. (2007) Positive association of schizophrenia to JARID2
gene. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B, 45–51
52 Berge-Lefranc, J.L. et al. (1996) Characterization of the human jumonji
gene. Hum. Mol. Genet. 5, 1637–1641
53 Bovill, E. et al. (2008) Induction by left ventricular overload and left
ventricular failure of the human Jumonji gene (JARID2) encoding a
protein that regulates transcription and reexpression of a protective
fetal program. J. Thorac. Cardiovasc. Surg. 136, 709–716
54 Shirato, H. et al. (2009) A jumonji (Jarid2) protein complex represses
cyclin D1 expression by methylation of histone H3-K9. J. Biol. Chem.
284, 733–739
55 Kim, T.G. et al. (2004) Jumonji represses atrial natriuretic factor gene
expression by inhibiting transcriptional activities of cardiac
transcription factors. Mol. Cell Biol. 24, 10151–10160
56 Jung, J. et al. (2005) Jumonji regulates cardiomyocyte proliferation via
interaction with retinoblastoma protein. J. Biol. Chem. 280, 30916–
30923
57 Kim, T.G. et al. (2005) Jumonji represses alpha-cardiac myosin heavy
chain expression via inhibiting MEF2 activity. Biochem. Biophys. Res.
Commun. 329, 544–553
58 Mysliwiec, M.R. et al. (2007) Characterization of zinc finger protein 496
that interacts with Jumonji/Jarid2. FEBS Lett. 581, 2633–2640
59 Barth, J.L. et al. (2010) Jarid2 is among a set of genes differentially
regulated by Nkx2.5 during outflow tract morphogenesis. Dev. Dyn.
239, 2024–2033
60 Kitajima, K. et al. (2001) A role of jumonji gene in proliferation but
not differentiation of megakaryocyte lineage cells. Exp. Hematol. 29,
507–514
61 Bolisetty, M.T. et al. (2009) Reticuloendotheliosis virus strain T
induces miR-155, which targets JARID2 and promotes cell survival.
J. Virol. 83, 12009–12017
62 Toyoda,M. et al. (2000) Jumonji is a nuclear protein that participates in
the negative regulation of cell growth. Biochem. Biophys. Res.
Commun. 274, 332–336
63 Anzai, H. et al. (2003) Impaired differentiation of fetal hepatocytes in
homozygous jumonji mice. Mech. Dev. 120, 791–800
64 Kim, J. et al. (2008) An extended transcriptional network for
pluripotency of embryonic stem cells. Cell 132, 1049–1061
65 Zhou, Q. et al. (2007) A gene regulatory network in mouse embryonic
stem cells. Proc. Natl. Acad. Sci. U. S. A. 104, 16438–16443
66 Loh, Y.H. et al. (2006) The Oct4 and Nanog transcription network
regulates pluripotency in mouse embryonic stem cells. Nat. Genet. 38,
431–440
67 Boyer, L.A. et al. (2005) Core transcriptional regulatory circuitry in
human embryonic stem cells. Cell 122, 947–956
68 Sun, Y. et al. (2008) Evolutionarily conserved transcriptional co-
expression guiding embryonic stem cell differentiation. PLoS One 3,
e3406
69 Kerppola, T.K. (2009) Polycomb group complexes –many combinations,
many functions. Trends Cell Biol. 19, 692–704
70 Sing, A. et al. (2009) A vertebrate Polycomb response element governs
segmentation of the posterior hindbrain. Cell 138, 885–897
71 Boyer, L.A. et al. (2006) Polycomb complexes repress developmental
regulators in murine embryonic stem cells. Nature 441, 349–353
72 Lee, T.I. et al. (2006) Control of developmental regulators by Polycomb
in human embryonic stem cells. Cell 125, 301–313
73 Azuara, V. et al. (2006) Chromatin signatures of pluripotent cell lines.
Nat. Cell Biol. 8, 532–538
74 Stock, J.K. et al. (2007) Ring1-mediated ubiquitination of H2A
restrains poised RNA polymerase II at bivalent genes in mouse ES
cells. Nat. Cell Biol. 9, 1428–143579
Opinion Trends in Cell Biology February 2011, Vol. 21, No. 275 Pasini, D. et al. (2007) The polycomb group protein Suz12 is required
for embryonic stem cell differentiation. Mol. Cell Biol. 27, 3769–3779
76 Shen, X. et al. (2008) EZH1 mediates methylation on histone H3 lysine
27 and complements EZH2 in maintaining stem cell identity and
executing pluripotency. Mol. Cell 32, 491–502
77 Bernstein, B.E. et al. (2006) A bivalent chromatin structure marks key
developmental genes in embryonic stem cells. Cell 125, 315–326
78 Mikkelsen, T.S. et al. (2007) Genome-wide maps of chromatin state in
pluripotent and lineage-committed cells. Nature 448, 553–560
79 Guenther, M.G. et al. (2007) A chromatin landmark and transcription
initiation at most promoters in human cells. Cell 130, 77–88
80 Buszczak, M. and Spradling, A.C. (2006) Searching chromatin for stem
cell identity. Cell 125, 233–2368081 Jaenisch, R. and Young, R. (2008) Stem cells, the molecular circuitry of
pluripotency and nuclear reprogramming. Cell 132, 567–582
82 Jorgensen, H.F. et al. (2006) Stem cells primed for action: polycomb
repressive complexes restrain the expression of lineage-specific
regulators in embryonic stem cells. Cell Cycle 5, 1411–1414
83 Panning, B. (2010) Fine-tuning silencing. Cell Stem Cell 6, 3–4
84 Pereira, C.F. et al. (2010) ESCs require PRC2 to direct the successful
reprogramming of differentiated cells toward pluripotency. Cell Stem
Cell 6, 547–556
85 Assou, S. et al. (2009) A gene expression signature shared by human
mature oocytes and embryonic stem cells. BMC Genomics 10, 10
86 Niwa, H. (2007) How is pluripotency determined and maintained?
Development 134, 635–646
